The FDA received a biologics license application for the accelerated approval of RP1 (vusolimogene oderparepvec) plus nivolumab (Opdivo) to treat adults with with advanced melanoma that was previously treated with a PD1 inhibitor.
Of Interest
Unexpected Findings in Study of T Cells, Considered Front-line Fighters Against Advanced Melanoma
Yale researchers made an unexpected discovery—turncoat T cells that help a tumor evade other cancer-fighting immune T cells—in a study of patients living with advanced melanoma that was published Nov. 28 in Nature Immunology.
Immune Cell Breakthrough: Scientists Discover a Hidden Ally in the Fight Against Cancer
Recent advances in immunotherapy research have revealed crucial roles for new immune cells in combating cancer, leading to potential strategies to enhance treatment efficacy and overcome resistance.
New Clinical Pathway Supports Cancer Recurrence Anxiety
Researchers have developed a three-step plan to support those burdened by the intense fear of cancer returning. This plan offers a consistent, streamlined approach to managing recurrence anxiety, empowering patients to regain confidence and move forward with their lives.